Longitudinal serum testosterone, luteinizing hormone, and follicle-stimulating hormone levels in a population-based sample of long-term testicular cancer survivors

Journal of Clinical Oncology

Volumn 32, Issue 6, 2014, Pages 571-578

  Sprauten, Mette ^a   Brydøy, Marianne ^d   Haugnes, Hege S ^e   Cvancarova, Milada ^a   Bjøro, Trine ^b   Bjerner, Johan ^c   Fosså, Sophie D ^a   Oldenburg, Jan ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c Furst Medical Laboratory   (Norway)

^d UNIVERSITY OF BERGEN   (Norway)

^e UNIVERSITY OF TROMSØ   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

FOLLITROPIN; LUTEINIZING HORMONE; PLATINUM; SEX HORMONE; TESTOSTERONE;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CANCER SURVIVOR; CONTROLLED STUDY; DISEASE COURSE; FOLLITROPIN BLOOD LEVEL; FOLLOW UP; GROUPS BY AGE; HEALTH CARE SURVEY; HORMONE DETERMINATION; HUMAN; HYPOGONADISM; LOGISTIC REGRESSION ANALYSIS; LONG TERM SURVIVAL; LUTEINIZING HORMONE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; ORCHIECTOMY; PATIENT RISK; POPULATION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; TESTIS CANCER; TESTOSTERONE BLOOD LEVEL; BLOOD; LONGITUDINAL STUDY; MIDDLE AGED; SURVIVOR; TESTIS TUMOR; YOUNG ADULT;

ADOLESCENT; ADULT; FOLLICLE STIMULATING HORMONE; HUMANS; LONGITUDINAL STUDIES; LUTEINIZING HORMONE; MALE; MIDDLE AGED; SURVIVORS; TESTICULAR NEOPLASMS; TESTOSTERONE; YOUNG ADULT;

EID: 84898549163     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.51.2715     Document Type: Article

References (43)

1. Oldenburg J, Fosså SD, Nuver J, et al: Testicular seminoma and non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 24:vi125-vi132, 2013
2. Eberhard J, Ståhl O, Cwikiel M, et al: Risk factors for post-treatment hypogonadism in testicular cancer patients. Eur J Endocrinol 158:561-570, 2008
3. Nord C, Bjøro T, Ellingsen D, et al: Gonadal hormones in long-term survivors 10 years after treatment for unilateral testicular cancer. Eur Urol 44:322-328, 2003 (Pubitemid 37051700)
4. Brydøy M, Fosså SD, Dahl O, et al. Gonadal dysfunction and fertility problems in cancer survivors. Acta Oncol 46:480-489, 2007 (Pubitemid 46752258)
5. Huddart RA, Norman A, Moynihan C, et al: Fertility, gonadal and sexual function in survivors of testicular cancer. Br J Cancer 93:200-207, 2005 (Pubitemid 41133206)
6. Eberhard J, Ståhl O, Cohn-Cedermark G, et al: Sexual function in men treated for testicular cancer. J Sex Med 6:1979-1989, 2009
7. Brydøy M, Fosså SD, Klepp O, et al: Paternity following treatment for testicular cancer. J Natl Cancer Inst 97:1580-1588, 2005 (Pubitemid 41662712)
8. Dahl AA, Bremnes R, Dahl O, et al: Is the sexual function compromised in long-term testicular cancer survivors? Eur Urol 52:1438-1447, 2007 (Pubitemid 47445974)
9. Hintikka J, Niskanen L, Koivumaa-Honkanen H, et al: Hypogonadism, decreased sexual desire, and long-term depression in middle-aged men. J Sex Med 6:2049-2057, 2009
10. Bhasin S, Cunningham GR, Hayes FJ, et al: Testosterone therapy in men with androgen deficiency syndromes: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 95:2536-2559, 2010
11. Rochira V, Balestrieri A, Madeo B, et al: Osteoporosis and male age-related hypogonadism: Role of sex steroids on bone (patho)physiology. Eur J Endocrinol 154:175-185, 2006
12. Haugnes HS, Aass N, Fosså SD, et al: Components of the metabolic syndrome in long-term survivors of testicular cancer. Ann Oncol 18:241-248, 2007 (Pubitemid 46323088)
13. Haugnes HS, Wethal T, Aass N, et al: Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: A 20-year follow-up study. J Clin Oncol 28:4649-4657, 2010
14. Haring R, Baumeister SE, Völzke H, et al: Prospective association of low total testosterone concentrations with an adverse lipid profile and increased incident dyslipidemia. Eur J Cardiovasc Prev Rehabil 18:86-96, 2011
15. Channer KS, Jones TH: Cardiovascular effects of testosterone: Implications of the "male menopause?" Heart 89:121-122, 2003 (Pubitemid 36115082)
16. Nuver J, Smit AJ, Wolffenbuttel BH, et al: The metabolic syndrome and disturbances in hormone levels in long-term survivors of disseminated testicular cancer. J Clin Oncol 23:3718-3725, 2005
17. Bjerner J, Biernat D, Fosså SD, et al: Reference intervals for serum testosterone, SHBG, LH and FSH in males from the NORIP project. Scand J Clin Lab Invest 69:873-879, 2009
18. Haugnes HS, Aass N, Fosså SD, et al: Predicted cardiovascular mortality and reported cardiovascular morbidity in testicular cancer survivors. J Cancer Surviv 2:128-137, 2008
19. Haugnes HS, Aass N, Fosså SD, et al: Pulmonary function in long-term survivors of testicular cancer. J Clin Oncol 27:2779-2786, 2009
20. Oldenburg J, Fosså SD, Dahl AA: Scale for chemotherapy-induced long-term neurotoxicity (SCIN): Psychometrics, validation, and findings in a large sample of testicular cancer survivors. Qual Life Res 15:791-800, 2006 (Pubitemid 43800751)
21. Oldenburg J, Kraggerud SM, Cvancarova M, et al: Cisplatin-induced long-term hearing impairment is associated with specific glutathione s-transferase genotypes in testicular cancer survivors. J Clin Oncol 25:708-714, 2007 (Pubitemid 350002927)
22. Oldenburg J, Kraggerud SM, Brydøy M, et al: Association between long-term neuro-toxicities in testicular cancer survivors and polymorphisms in glutathione-s-transferase-P1 and -M1, a retrospective cross sectional study. J Transl Med 5:70, 2007
23. Wethal T, Haugnes HS, Kjekshus J, et al: C-reactive protein; a potential marker of second cancer and cardiovascular disease in testicular cancer survivors? Eur J Cancer 46:3425-3433, 2010
24. Dahl AA, Haaland CF, Mykletun A, et al: Study of anxiety disorder and depression in long-term survivors of testicular cancer. J Clin Oncol 23:2389-2395, 2005 (Pubitemid 46218733)
25. Brydøy M, Oldenburg J, Klepp O, et al: Observational study of prevalence of long-term Raynaud-like phenomena and neurological side effects in testicular cancer survivors. J Natl Cancer Inst 101:1682-1695, 2009
26. Sprauten M, Darrah TH, Peterson DR, et al: Impact of long-term serum platinum concentrations on neuro- and ototoxicity in cisplatin-treated survivors of testicular cancer. J Clin Oncol 30:300-307, 2012
27. Cullen MH, Stenning SP, Parkinson MC, et al: Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: A Medical Research Council report. J Clin Oncol 14:1106-1113, 1996 (Pubitemid 26105516)
28. Fosså SD, Horwich A, Russell JM, et al: Optimal planning target volume for stage I testicular seminoma: A Medical Research Council randomized trial - Medical Research Council Testicular Tumor Working Group. J Clin Oncol 17:1146, 1999
29. [No authors listed]: International Germ Cell Consensus Classification: A prognostic factor-based staging system for metastatic germ cell cancers - International Germ Cell Cancer Collaborative Group. J Clin Oncol 15:594-603, 1997
30. Fosså SD, Stenning SP, Gerl A, et al: Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours. Br J Cancer 80:1392-1399, 1999 (Pubitemid 29308608)
31. Go RS, Adjei AA: Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol 17:409-422, 1999 (Pubitemid 29022420)
32. Lokich J, Anderson N: Carboplatin versus cisplatin in solid tumors: An analysis of the literature. Ann Oncol 9:13-21, 1998 (Pubitemid 28125759)
33. Travis LB, Holowaty EJ, Bergfeldt K, et al: Risk of leukemia after platinum-based chemotherapy for ovarian cancer. N Engl J Med 340:351-357, 1999 (Pubitemid 29090800)
34. Ozols RF, Behrens BC, Ostchega Y, et al: High dose cisplatin and high dose carboplatin in refractory ovarian cancer. Cancer Treat Rev 12:59-65, 1985 (Pubitemid 16167901)
35. Djaladat H, Nichols C, Daneshmand S: Androgen-producing testicular germ cell tumors. J Clin Oncol 29:e634-e635, 2011
36. Petersen PM, Skakkebaek NE, Vistisen K, et al: Semen quality and reproductive hormones before orchiectomy in men with testicular cancer. J Clin Oncol 17:941-947, 1999 (Pubitemid 29109327)
37. Skakkebaek NE, Rajpert-De Meyts E, Main KM: Testicular dysgenesis syndrome: An increasingly common developmental disorder with environmental aspects. Hum Reprod 16:972-978, 2001 (Pubitemid 32451837)
38. Bandak M, Aksglaede L, Juul A, et al: The pituitary-Leydig cell axis before and after orchiectomy in patients with stage I testicular cancer. Eur J Cancer 47:2585-2591, 2011
39. Dueland S, Guren MG, Olsen DR, et al: Radiation therapy induced changes in male sex hormone levels in rectal cancer patients. Radiother Oncol 68:249-253, 2003 (Pubitemid 38373425)
40. Jacobsen KD, Olsen DR, Fosså K, et al: External beam abdominal radiotherapy in patients with seminoma stage I: Field type, testicular dose, and spermatogenesis. Int J Radiat Oncol Biol Phys 38:95-102, 1997 (Pubitemid 27270947)
41. Calof OM, Singh AB, Lee ML, et al: Adverse events associated with testosterone replacement in middle-aged and older men: A meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci 60:1451-1457, 2005 (Pubitemid 41798454)
42. Dohle GR, Arver S, Bettocchi C, et al: Guidelines on male hypogonadism. Arnhem, the Netherlands, European Association of Urology, 2012
43. Haugnes HS, Bosl GJ, Boer H, et al: Long-term and late effects of germ cell testicular cancer treatment and implications for follow-up. J Clin Oncol 30:3752-3763, 2012